Castle Biosciences Reports Strong Q2 Revenue Growth and Raises Full-Year Outlook
Castle Biosciences reported second-quarter revenue of $103.5 million for fiscal year 2026, representing a 20% increase compared to the same period in 2025. The growth was primarily driven by its TissueCypher test, which generated 14,988 reports—a 63% rise from last year—and is expected to grow between 50% and 52% for the full year. Despite strong revenue performance, gross margins declined slightly due to operational costs, resulting in a $2.1 million net loss. However, adjusted EBITDA improved significantly to $12.4 million. The company raised its annual revenue guidance from $345–$355 million to $365–$375 million for 2026 and expects positive adjusted EBITDA in the third quarter, fourth quarter, and full year of 2026. CEO Derek Maetzold highlighted continued investment in commercial resources, clinical evidence development, pipeline programs, and laboratory capacity as key drivers behind strong performance. Castle Biosciences also noted progress across its dermatology offerings, including AdvanceAD-Tx surpassing 1,000 orders during the quarter.
Tickers: $CSTL
Topics: biotech ebitda financial_results revenue_growth